Beraprost-d3

• Description :

  Beraprost-d3 (TRK-100-d3) is deuterium labeled (Rac) -Beraprost. (Rac) -Beraprost ((Rac) -ML 1229) is an orally active prostacyclin analog that inhibits the release of Ca2+ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis[1].

• Product Name Alternative :

  TRK-100-d3; ML 1129-d3

• UNSPSC :

  12352005

• Target :

  Isotope-Labeled Compounds; Prostaglandin Receptor

• Related Pathways :

  GPCR/G Protein; Others

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Smiles :

  O=C(CCCC1=CC=CC2=C1OC3CC(C(C23)/C=C/C(C(CC#CC)C([2H])([2H])[2H])O)O)O

• Molecular Formula :

  C24H27D3O5

• Molecular Weight :

  401.51

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Li S, et al. Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels. J Mol Med (Berl) . 2019 Jun;97 (6) :777-791.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported